| Program |
|
Wednesday, September 8, 2010 16:00 - 20:00 Registration & Badges withdrawal Thursday, September 9, 2010 08:00 - 09:00 For and Against Session I: How often should we use the remodeling technique, always (almost always) or only in specific indications? • 08:00 - 08:15 : For L. PIEROT, France • 08:15 - 08:30 : Against M. CRONQVIST, Sweden • 08:30 - 09:00 : Discussion and participants case presentation on remodeling technique 09:00 - 10:00 For and Against Session II: Should we use stents in ruptured aneurysms? • 09:00 - 09:15 : For V. KATSARIDIS, Greece • 09:15 - 09:30 : Against M. BENDSZUS, Germany • 09:30 - 10:00 : Discussion and participants case presentation on Stents in ruptured aneurysms 10:00 - 10:15 Coffee break 10:15 - 11:00  Boston Scientific Symposium: "Advances in Intracranial Stenting"• Safety and Efficacity of Neuroform™3 for Intracranial Aneurysms Treatment: The S.E.N.A.T. study A. BONAFÉ, France • Lessons learned from Eight Years of Clinical Experience using the Neuroform™ Stent for the Treatment of Cerebral Aneurysms and Latest Experience with the Neuroform EZ™ Stent System D.K. LOPES, United States 11:00 - 12:00 BAVM treatments: Interesting cases, morbi-mortality and presentation of complications Chairman: A. BIONDI, France 12:00 - 13:00 Recent controversies in large trials Chairman: J. BYRNE, United Kingdom • 12:00 - 12:07 : Carotid stenting: Are European and American Studies saying different things? J. FIEHLER, Germany • 12:08 - 12:12 : All trials are saying the same thing: Endarterectomy wins! J. RAYMOND, Canada • 12:13 - 12:20 : Discussion • 12:20 - 12:27 : Bioactive coils (Cerecyte and Matrix): There is no evidence they should be used P. WHITE, United Kingdom • 12:28 - 12:35 : Helps results: should we now use only hydrogel? J. RAYMOND, Canada • 12:36 - 12:39 : Coil choices should be based on clinical preferences J. FIEHLER, Germany • 12:40 - 12:45 : Discussion • 12:45 - 12:50 : Premature trials cannot be used as case against a technique J. FIEHLER, Germany • 12:51 - 12:56 : Management trials (Team and Aruba): who has the burden of the proof? P. WHITE, United Kingdom • 12:57 - 13:00 : Discussion 13:00 - 14:00 Lunch 14:00 - 16:00 How I do it sessions: In the absence of "Evidence", how do we select candidates for IA recanalization? Moderators: I. GRUNWALD, United Kingdom - V. MENDES PEREIRA, Switzerland Panelists: A. BONAFÉ, France - I. GRUNWALD, United Kingdom - M. KILLER, Austria - V. MENDES PEREIRA, Switzerland • 14:00 - 14:40 : Panelists will discuss their own protocol for IA stroke treatment and specially how they select patients: stroke severity (NIHSS score, Aspects score), imaging modality (MR/CT), dose of IV rTPA, how to evaluate the efficiency of IV rTPA (Is it useful before deciding for IA?), technique of thrombectomy • 14:40 - 15:00 : Experimental work on the biomechanics of Clot A. WAKHLOO, United States • 15:00 - 16:00 : Interesting cases, morbi-mortality and complications presentations on acute stroke treatment 16:00 - 16:30 Coffee break 16:30 - 17:15  ev3 Symposium: "New Technologies and Techniques in Neurovascular Intervention"• New Intra-arterial Mechanical Therapy with High Efficacy, Safety and Fast Speed of Treatment... Montpellier Solitaire FR Stroke Experience A. BONAFÉ, France • Axium MicroFX in the Treatment of Intracranial Aneurysm: Early Clinical Experience J. BHATTACHARYA , United Kingdom • Questions & Answers 17:15 - 18:00 The best success of the year! A lesson or technique to learn! Faculty or participants' cases Chairman: I. WANKE, Switzerland 18:15 - 19:30 ESMINT Executive Committee Meeting Friday, September 10, 2010 08:00 - 08:45 Flow diverters Panelists: J. BERGE, France - S. CEKIRGE, Turkey - R. CHAPOT, Germany - Z. KULCSAR, Switzerland - J. MORET, France - J. RAYMOND, Canada - L. SPELLE, France - I. SZIKORA, Hungary • 08:00 - 08:15 : Presentation of results using Flow Diverter devices: Ongoing or reported studies I. SZIKORA, Hungary • 08:15 - 08:30 : How much should we divert the flow? On which evidence: Flow dynamic modeling or animal studies? J. RAYMOND, Canada • 08:30 - 08:45 : A different thrombus biology after FD? J. BERGE, France 08:45 - 10:00 Flow diverters: 15 mn presentations followed by participants' cases on... Panelists: J. BERGE, France - S. CEKIRGE, Turkey - R. CHAPOT, Germany - Z. KULCSAR, Switzerland - J. MORET, France - J. RAYMOND, Canada - L. SPELLE, France - I. SZIKORA, Hungary • Risk of rupture of unruptured aneurysms after FD: Should we coil before using a FD? J. MORET, France • Risk of acute and delayed aneurysm thrombosis and complications? J. MORET, France 10:00 - 10:30 Coffee break 10:30 - 13:00 Flow diverters: 15 mn presentations followed by participants' cases on... Panelists: J. BERGE, France - S. CEKIRGE, Turkey - R. CHAPOT, Germany - Z. KULCSAR, Switzerland - J. MORET, France - J. RAYMOND, Canada - L. SPELLE, France - I. SZIKORA, Hungary • Risk of FD occlusion? L. SPELLE, France • Risk of perforators' occlusion? Z. KULCSAR, Switzerland • Should we use FD in bifurcations? R. CHAPOT, Germany • FD or "homemade" FD with multiple stents? S. CEKIRGE, Turkey 13:00 - 14:00 Lunch 14:00 - 15:30 How should we start using new devices? Chairmen: C. COGNARD, France - A. WAKHLOO, United States • Introduction C. COGNARD, France • Health care European regulation: What is recommended by law? What should be done in Practice J.C. GHISLAIN, France • An industry presentation: A summary of development and regulatory process of a medical device R. ALLEN, United States • What do interventional Cardiologists do? • Which guidelines should we established for new devices evaluation? J. FIEHLER, Germany - L. PIEROT, France - J. RAYMOND, Canada - A. WAKHLOO, United States • Round Table: Should the ESMINT establish recommendations for evaluation of new devices. Obligatory inclusion of all consecutives cases in registries with an independent clinical evaluation? When should we randomize? Is randomization feasible for all neurovascular pathologies? How to design a randomized study? Who should pay for evaluation? R. ALLEN, United States - C. COGNARD, France - J. FIEHLER, Germany - J.C. GHISLAIN, France - I. GRUNWALD, United Kingdom - J. MORET, France - J. RAYMOND, Canada - A. WAKHLOO, United States - P. WHITE, United Kingdom - &. EVERYBODY 15:30 - 16:00 The worse complication of the year! The big mistakes to avoid! Chairman: C. ISLAK, Turkey 16:00 - 16:30 Coffee break 16:30 - 17:30 Intradural Spinal AV shunts: When and How to treat them? Chairman: A. CASASCO, Spain • Interesting cases, morbi-mortality and complications presentations on spinal AV shunts 17:30 - 18:30 ESMINT General Assembly 20:00 Gala Dinner Saturday, September 11, 2010 08:30 - 10:00 Interesting cases, morbi-mortality and complications presentations on what you want! Chairman: E. BOCCARDI, Italy 10:00 - 10:30 Coffee break 10:30 - 12:00 Quiz Chairmen: G. GAL, Denmark - A. GRÜBER, Austria • A session of test cases available to participants in advance. A panel of 8 so called experts will give their analysis of each case and suggest a management plan. The convener will then outline what happened and how the problem was resolved. 12:00 Closing Cocktail in the exhibition area
|
|
|||
